Neurology
SCAI guidelines for the management of patent foramen Ovale.
20 May, 2022 | 11:01h | UTCSCAI Guidelines for the Management of Patent Foramen Ovale – JSCAI
Editorial: New SCAI Guidelines: Trying to Close the Holes in the PFO Literature – JSCAI
Commentary: PFO Closure Guidelines Address Older Adults, Trial-Excluded Groups— Document acknowledges skimpy evidence – MedPage Today (free registration required)
Related:
Advances in the management of cardioembolic stroke associated with patent foramen ovale – The BMJ
Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke – JAMA (link to abstract – $ for full-text)
M-A: Comparison of Amitriptyline with other FDA–approved treatments for fibromyalgia.
20 May, 2022 | 10:49h | UTC
RCT: Tenecteplase vs. alteplase for the management of acute ischemic stroke.
20 May, 2022 | 10:43h | UTCTenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)
Systematic Review | Post-stroke dysphagia: prognosis and treatment.
20 May, 2022 | 10:33h | UTC
Systematic Review: Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis.
20 May, 2022 | 10:28h | UTCPercutaneous transluminal angioplasty and stenting for vertebral artery stenosis – Cochrane Library
Summary: Endovascular treatment for vertebral artery stenosis – Cochrane Library
Discovery reveals blocking inflammation may lead to chronic pain.
19 May, 2022 | 11:06h | UTCNews Release: Discovery reveals blocking inflammation may lead to chronic pain – McGill University
Original Study: Acute inflammatory response via neutrophil activation protects against the development of chronic pain – Science Translational Medicine
Commentary on Twitter
Challenging medical dogma:
A very important new report suggests that non-steroidal inflammatory medications for acute pain can lead to chronic painhttps://t.co/Z8yjFFBCkK @ScienceTM https://t.co/YGjkXbvNTa pic.twitter.com/f4xVezAhau— Eric Topol (@EricTopol) May 18, 2022
RCT: An intervention to promote self-management, independence and self-efficacy in people with early-stage dementia did not improve clinical outcomes.
19 May, 2022 | 10:42h | UTC
Psychogenic nonepileptic seizure: An empathetic, practical approach.
19 May, 2022 | 10:30h | UTCEditorial: Psychogenic nonepileptic seizure: A neurologist’s perspective
AHA/ASA Guideline: Management of patients with spontaneous intracerebral hemorrhage.
18 May, 2022 | 12:01h | UTCTop Things to Know: 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage – American Heart Association
News Release: New guideline refines care for brain bleeds: compression socks, some meds not effective – American Heart Association
Commentary on Twitter
Released today: Guidelines for treating spontaneous ICH
Includes:
➡️ Acute reversal of anticoagulation after ICH
➡️Updates to common interventions
➡️Minimally invasive surgical recommendations✍️ @SMGreenbergNeur @WendyZiai
? @StrokeAHA_ASA https://t.co/6YQ2TLy3NW pic.twitter.com/y93qQGCmfV
— AHA Science (@AHAScience) May 17, 2022
Retrospective Cohort Study: Association of race and ethnicity with incidence of dementia among older adults.
17 May, 2022 | 10:29h | UTCAssociation of Race and Ethnicity With Incidence of Dementia Among Older Adults – JAMA (link to abstract – $ for full-text)
News Release: Cross-racial study of 1.87m vets shows wide disparities in dementia – University of California – San Francisco
Commentaries:
Significant Differences in Dementia Incidence Based on Race and Ethnicity – NeurologyToday
Strong evidence for differences in dementia risk by race and ethnicity – MedicalResearch
Dementia Incidence Varies by Race, Ethnicity – HealthDay
Commentary on Twitter
In this retrospective cohort study, among adults who received care at Veterans Health Administration medical centers, significant differences in #dementia incidence existed based on race and ethnicity. https://t.co/WguRziHyMa
— JAMA (@JAMA_current) April 25, 2022
M-A: Efficacy and tolerability of repetitive transcranial magnetic stimulation on suicidal ideation.
17 May, 2022 | 10:25h | UTC
Commentary on Twitter
MA: rTMS significantly reduced suicidal ideation (g= −0.390; −0.193 to −0.588) and severity of depressive symptoms (g= −0.698; −1.023 to −0.372) in patients with major mental disorders https://t.co/TBSfG5GIL0 pic.twitter.com/QX06EX8Hog
— PfOL (@psychopharmacol) May 11, 2022
Under a CC BY license
ESC Position Paper: Integrated care for optimizing the management of stroke and associated heart disease.
16 May, 2022 | 02:29h | UTC
Commentary on Twitter
Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Strokehttps://t.co/L7dPxM6dZx#EHJ #stroke @escardio @ESC_Journals #CardioTwitter pic.twitter.com/MB6mIqzdui
— EHJ Editor-in-Chief (@ehj_ed) May 14, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
RCT: Efficacy and safety of ultrahigh-dose Methylcobalamin in early-stage amyotrophic lateral sclerosis.
16 May, 2022 | 02:02h | UTCEfficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
A phase 3 clinical trial found ultra-high dose methylcobalamin slowed functional decline in patients with early-stage amyotrophic lateral sclerosis. https://t.co/r5KP38JkUc
— JAMA Neurology (@JAMANeuro) May 9, 2022
Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
16 May, 2022 | 01:45h | UTC
Commentary on Twitter
SR: there is moderate evidence of the efficacy of gabapentinoids in anxiety states (SMD ranging between -2.25 and -0.25), but minimal evidence in bipolar disorder and insomnia and they should be used for these disorders only with strong justification https://t.co/zrxduX2q6l pic.twitter.com/6mKYwHKKbo
— PfOL (@psychopharmacol) May 12, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
RCT: Efficacy and safety of fenfluramine for the treatment of seizures associated With Lennox-Gastaut Syndrome.
16 May, 2022 | 01:29h | UTCCommentaries:
Fenfluramine Found Effective for Treatment of Lennox-Gastaut Syndrome Seizures – NeurologyToday
Fenfluramine Seems Effective for Lennox-Gastaut Syndrome – HealthDay
Commentary on Twitter
In this randomized clinical trial, fenfluramine was a safe and effective treatment option for patients with Lennox-Gastaut syndrome. https://t.co/Ukopx9cV9r @Zogenix pic.twitter.com/dRetoOZSiB
— JAMA Neurology (@JAMANeuro) May 2, 2022
Review: Radiological assessment of chronic subdural hematomas.
16 May, 2022 | 01:17h | UTCRadiological Assessment of Chronic Subdural Hematomas – Korean Journal of Neurotrauma
Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US.
13 May, 2022 | 10:55h | UTCRisk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US – JAMA Neurology (free for a limited period)
Commentaries:
Alzheimer’s and Dementia Linked to Eight Modifiable Risk Factors – Psychiatric News Alert
The 3 Midlife Factors That Raise Your Odds for Alzheimer’s – HealthDay
M-A: Comparative impact of pharmacological therapies on cluster headache management.
12 May, 2022 | 08:01h | UTC
Systematic Review: Prevention of peripheral distal polyneuropathy in patients with diabetes.
12 May, 2022 | 07:58h | UTC
Rapidly progressive dementias — etiologies, diagnosis and management.
10 May, 2022 | 10:59h | UTCRapidly progressive dementias — aetiologies, diagnosis and management – Nature Reviews Neurology (if the link is paywalled, try this one in PMC)
Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.
10 May, 2022 | 10:32h | UTC
RCT: Terminal complement inhibitor Ravulizumab in generalized myasthenia gravis.
9 May, 2022 | 01:27h | UTCTerminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis – NEJM Evidence
Commentary on Twitter
In this RCT, Ravulizumab provided rapid and efficacious treatment of adult patients with anti-AChR antibody-positive generalized myasthenia gravis (gMG), as determined by both patient- and clinician-rated outcomes, with few adverse events. https://t.co/9mlCOULiJR#NeuroTwitter pic.twitter.com/ZljrTs282f
— NEJM Evidence (@NEJMEvidence) May 3, 2022
Systematic Review: Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
6 May, 2022 | 10:47h | UTCSummary: Cannabis and cannabinoids for people with multiple sclerosis – Cochrane Library
Commentary on Twitter
?A UK survey found that 1 in 5 people with #MS reported they used #Cannabis to manage symptoms.
? Does it work? Are there harms?
? Cochrane systematic review looks at 25 RCTs ➡️ https://t.co/HCt6Cx3suo#MedicalMarijuana #MultipleSclerosis pic.twitter.com/wjDTXXEciM— The Cochrane Library (@CochraneLibrary) May 5, 2022
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.
5 May, 2022 | 10:22h | UTC
Management of patients presenting to the emergency department with sudden onset severe headache: systematic review of diagnostic accuracy studies.
5 May, 2022 | 10:08h | UTC